SoftBank Group will introduce a medical service backed by artificial intelligence in Japan via its new joint venture with U.S. healthcare firm Tempus AI. The new company will analyze patients' data, such as genetic information and other medical records, using Tempus's artificial intelligence and offer doctors options for treatments. The joint venture will be capitalized at ¥30 billion, equivalent to $187 million.

SoftBank and Tempus will each own a 50% stake.